Possible contribution of epigenetic changes in the development of schizophrenia-like behavior in vasopressin-deficient Brattleboro rats by Demeter, Kornél et al.
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AVP  deﬁcient  Brattleboro  rat  strain  is  a valuable  model  to  study  schizophrenia.
Lack  of  AVP  resulted  in  changes  of  histone  acetylation  in  the  frontal  brain and  hippocampus.
Inﬂuencing  histone  acetylation  may  provide  therapeutic  alternatives  for  schizophrenia.
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a  b  s  t  r  a  c  t
Schizophrenia-like  symptoms  were  detected  in vasopressin-deﬁcient  (di/di)  Brattleboro  rats,  and  it  was
also  suggested  that  schizophrenia  might  have  an  epigenetic  component.  We  aimed  to  clarify  if epigenetic
changes  contribute  to schizophrenia-like  behavior  of  this  strain.
Behavioral  (locomotion  by telemetry,  cognition  by novel  object  recognition,  social  recognition  and
social  avoidance  test,  attention  by pre-pulse  inhibition)  and epigenetic  differences  were  compared
between  wild  type  and  di/di  animals.  DNA  methyltransferase1  (DNMT1),  DNMT3a,  as  well  as  COMT,
GAD,  VGLUT1,  5HT2A,  BDNF  mRNA  levels  in prefrontal  brain  region  and  hippocampus  were  studied  by
qRT-PCR.  Histone3  (H3)  and H4  acetylation  (Ac)  were  studied  by  western-blot  followed  by  region  speciﬁc
examination  of  H3  lysine9  (K9)  acetylation  by  immunohistochemistry.
Impaired  cognitive,  social  and  attention  behavior  of di/di  rats  conﬁrmed  schizophrenia-like  symptoms
in  our  local  colony.  The  pan-AcH3  immunoreactivity  was  lower  in  prefrontal  region  and  elevated  in  the
hippocampus  of di/di animals.  We  found  lower  immunopositive  cell  number  in  the dorsal  peduncular
prefrontal  cortex  and  the  ventral  lateral  septum  and  increased  AcH3K9  immunoreactivity  in  CA1  region
of di/di  animals.  There  were  no major  signiﬁcant  alterations  in  the  studied  mRNA  levels.We conﬁrmed  that  Brattleboro  rat  is  a good  preclinical  model  of  schizophrenia.  Its  schizophrenia-
like behavioral  alteration  was  accompanied  by  changes  in  H3  acetylation  in  the  prefrontal  region  and
hippocampus.  This  may  contribute  to disturbances  of  many  schizophrenia-related  substances  leading  to
development  of  schizophrenia-like  symptoms.  Our  studies  conﬁrmed  that  not a single gene,  rather  ﬁne
leculchanges  in  an  array  of mo
. IntroductionSchizophrenia (SCZ), one of the major psychoses, affects more
han 1% of the whole human population [1,2]. SCZ patients are char-
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acterized by delusions, hallucinations, disorganized speech and
behavior etc. [3]. These symptoms also include social dysfunction,
which additionally affects family members and burden the society.
Despite the importance, there is no cure for SCZ. Many partially
effective therapies exist, but none can guarantee a cure to a spe-
ciﬁc case of the disease. The mechanism of all recently available
antipsychotic drugs was  discovered 60 years ago [4,5], their main
therapeutic effect is the blockade of dopaminergic receptors [6].
A fundamental barrier to new drug development for the treat-
ment of major psychiatric disorders was  and still is an incomplete
1  Brain 
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nderstanding of the ethiopathogenetic mechanisms underlying
he symptomatology of these diseases.
The epigenetic hypothesis provides an integrative theory for
CZ [7–9] unifying the multifactorial origin under a common
ramework [10,11]. Genetic studies have linked many genes and
hromosomal regions distributed throughout the genome to SCZ,
ut no single or small number of genes accounts for the major-
ty of cases [6,12]. According to the biopsychosocial model of
ngel perinatal development is a determining factor for later
ccurrence of psychiatric disorders [13]. Especially during this
eriod (but also later in life) environmentally induced epigenetic
hanges may  activate (e.g., histone acetylation by acetyltransferase
HAT)) or inhibit (e.g., DNA methylation by DNA methyltrans-
erases (DNMT) or histone deacetylation by deacetylases (HDAC))
he expression of different genes [14,15]. Therefore on the same
enetic background different susceptibility to SCZ-inducing life
vents may  develop [16]. As developmental disturbances are core
eatures of SCZ, and epigenetic changes occur globally in early
evelopment acting as interface between the environment and
he genome [17], we might assume that epigenetic rather than
enetic changes have general ethiopathogenic role. Indeed, the
rst suggestion on the epigenetic aspect of SCZ goes back to
he early 60s, when enhancing DNA methylation by methionine
dministration was shown to exacerbate psychotic symptoms
18]. Since then many studies found epigenetic modiﬁcations in
CZ patients, as well as in animal models (for a review see e.g.,
ur book chapter [14]). The importance of epigenetic theory is
hat epigenetic processes are highly dynamic unlike the DNA
equence of a cell, which is stable and strongly conserved. There-
ore epigenetic disruptions may  develop relatively fast and are
otentially reversible, thus a realistic target for pharmacologi-
al intervention. Indeed, the fact that antipsychotics are clinically
ffective just after prolonged treatment, and—similarly—more time
s needed for the development of epigenetic changes, suggests that
ne of the main target of these drugs might be the epigenome
19–21].
Development of new drugs requires animal models. Genetic
odels have the advantage that the SCZ-inducing intervention
oes not interfere with the treatment drug. However, one might
ssume that the perinatal development of these animals is simi-
arly important leading to epigenetic changes on a disturbed genetic
ackground. Here we were focusing on the arginine vasopressin
AVP) deﬁcient (di/di) Brattleboro rat strain. Reduced level of this
ocial hormone [22–26], or its carrier, neurophysin [24] was found
n SCZ patients. Later studies revealed an association between AVP
ene [27] or AVP 1a receptor [28,29] and some behavioral dys-
unction (e.g., pre-pulse inhibition (PPI)). Moreover, some of the
CZ-symptoms were ameliorated by treatment with AVP analogs
30–35]. However, other studies found elevated levels [36,37] or
o beneﬁcial effect of the AVP treatment [38], therefore direct
athogenic role of AVP-deﬁciency in the development of symptoms
s not evident.
Nevertheless, the AVP-deﬁcient Brattleboro rat shows SCZ-
elated symptoms, which develop spontaneously. This strain, in
ddition to exhibiting a diabetes insipidus-like phenotype char-
cterized by polydipsia and polyuria, have been shown to have a
umber of cognitive and behavioral abnormalities that are anal-
gous to those seen in SCZ patients, including abnormalities in
emory, emotional reactivity, social recognition, motivation and
ttention [39–44]. As AVP is not clearly connected to disease eti-
logy, epigenetic contribution is more likely leading to secondary
hanges in different neurotransmitter systems [45,46].We hypothesized, that epigenetic changes as some particular
NA and histone modiﬁcations, may  contribute to the develop-
ent of SCZ-like symptoms in this animal model. We  focused
n the frontal part of the brain (FB) as the main area thoughtResearch 300 (2016) 123–134
to be involved in SCZ [47] and associated mostly with epigenetic
changes in this disorder [14,48,49]. However, the current litera-
ture does suggest that alterations are not isolated to a few brain
regions, but are characterized by abnormalities within brain net-
works [50], like the hippocampo-prefrontal cortex (PFC) system
[51]. Thus, we studied the hippocampus (HC) as well, as one of
the main center of memory [52], because cognitive deﬁcits are
most predictive of long-term outcomes of SCZ. According to recent
ﬁndings cortical GABAergic deﬁcit dominates SCZ pathophysiology
[53], therefore we examined its detection marker, the synthetiz-
ing enzyme glutamate decarboxylase (GAD1), the isoform known
to be downregulated in PFC [54] and HC [55] of SCZ patients. In
relation with the dopaminergic, glutamatergic and serotonergic
neurotransmitter systems, cathecol-o-methy-transferase (COMT),
vesicular glutamate transporter1 (VGLUT1) and 5HT2A recep-
tor mRNA levels were studied respectively. Neurodevelopmental
changes were examined by changes in brain derived neurotrophic
factor (BDNF) mRNA. Methylation changes of these special genes
were observed mostly in relation to SCZ [14].
2. Materials and methods
2.1. Animals
Adult, male Brattleboro rats (∼330 g, 10–12 weeks old) were
maintained in our institute [56] in a colony started from breeder
rats from Harlan, Indianapolis, IN, USA. Rats were kept in conven-
tional plastic cages (30 × 40 cm)  among controlled environment
(23 ± 1 ◦C, 50–70% humidity, 12 h light starting at 07:00 h) and
given commercial rat chow (Charles River, Budapest, Hungary) and
tap water ad libitum. We  compared the AVP deﬁcient homozy-
gous (di/di) rats with diabetes insipidus to homozygous normal
(+/+) control rats. All experiments were conducted in the morn-
ing between 09:00 and 12:00 h. The experiments were performed
in accordance with regulations set by the European Communities
Council Directive (2010/63/EU) and were approved by our Institu-
tional Animal Care and Use Committee.
2.2. Biotelemetry
Locomotor activity was monitored via implanted biotelemetry
emitters (Minimitter Co., Bend, OR, USA) as described earlier [57].
In brief, the emitter was  placed into the abdominal cavity of rats
through a midline abdominal incision under Ketamin (50 mg/kg;
Produlab Pharma b.v., Netherlands), Xylasine (10 mg/kg; Produlab
Pharma b.v., Netherlands), and Pipolphen (5 mg/kg; Egis Phar-
maceuticals PLC, Hungary) anesthesia. Biotelemetric recordings
started 2 weeks later and were made by means of a 12-channel
VitalView system (Minimitter Co.). Daily activity was  monitored for
24 h, started in the ﬁrst hour of dark period, visualized in Zeitgeber
time.
2.3. Behavioral tests
2.3.1. Novel object recognition test (NOR)
The rats were singly habituated to the experimental cages
(41.3 × 26 × 29.8 cm,  GeoMaxi, Ferplast, Italy) with fresh bedding
1 h before starting the test. For the object related equivalent of
social discrimination we  developed an experimental design com-
parable to the social paradigm in both time course and test settings
[58]. Two different objects were used: a 62 g tin box and an 80 g
bottle of tomato sauce. One of this objects (Object 1) was  pre-
sented for 4 min  (sampling phase), than removed, and 30 min later
the same (Object 1) and a different object (Object 2) were intro-
duced to the rat for 4 min. The objects were thoroughly cleaned
with alcohol before each animal. The tests were videotaped and
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nalyzed later by an experimenter blind to the treatments by means
f a computer-based event recorder (H77, Budapest, Hungary). In
ehavior directed toward the object we distinguished snifﬁng and
nawing as an important component. To exclude object prefer-
nce the two objects were randomly used as Object 1 or Object
. Discrimination index was calculated as follows: (time percent-
ge Object 2 − time percentage Object 1)/(time percentage Object
 + time percentage Object 2) × 100. The result of the index changes
etween −100% and +100%, where 0 = no discrimination. Normally
he animals spend more time with the new stimulus (novelty
ffect), thus the index around or below 0 is a sign of memory deﬁcit.
.3.2. Social recognition test (SR)
Like in the NOR test, after the habituation period, instead of the
bjects, a juvenile rat (average 20 days old) was placed into the cage
or 4 min  (sampling phase) [59]. After a 30-min inter-trial interval
he juvenile from trial 1 (old) plus a novel juvenile were placed there
or 4 min  (juveniles were marked with different colors). Both 4 min
ere video-recorded and later the amount of interaction was mea-
ured. The ﬁrst session shows social interaction tendency in a novel
nvironment and the second one shows the discrimination capabil-
ty between the two juveniles. Discrimination index was  calculated
s above in NOR.
.3.3. Social avoidance (SA)
The test was performed as described earlier [57]. Brieﬂy,
ats were studied in two plastic cages connected by a slid-
ng door. The subject was placed in the smaller cage (surface:
5 cm × 50 cm × 40 cm)  for a 3 min  habituation period. The larger
age (40 cm × 40 cm × 40 cm)  was divided into two  equal com-
artments by a transparent, perforated plastic wall. The distant
ompartment contained a large unfamiliar male. After the habit-
ation period, the sliding door was removed, and the subject was
llowed to explore the cage for 5 min. The test apparatus did not
ermit physical contact between the experimental and stimulus
nimals. Behavior was video-recorded from above and analyzed
ater. Three variables were recorded: the frequency of visits made
o the compartment containing the opponent as well as duration
nd the interaction with unfamiliar male (opponent entries and
ime% spent with opponent, respectively).
.3.4. Prepulse inhibition (PPI)
The Colbourne Instruments (USA) Acoustic Startle setup was
sed in our experiments. After a weight calibration subjects were
laced in a test cage on an instrument measuring the startle
esponse (by recording small changes in weight) inside a sound
ttenuated chamber. Following 5 min  of habituation subjects were
resented 40 ms  long, 120 dB acoustic stimuli (noise) for 5 times in
very 20 sec to standardize startle. Five trial types were then pre-
ented during testing: (i) 40 ms  long 120 dB startle pulse without
repulse, (ii–iv) 40 ms  120 dB pulse preceded 80 ms  by a 20 ms  pre-
ulse (tone) of three varying intensity (73, 77 or 81 dB) and (v) a trial
ith no prepulse and 0 dB pulse. Trials were repeated until every
ype of trials was presented 5 times. Different animals received
ifferent trial types in a different, randomized order. Immedi-
tely afterwards other four trial types were randomly applied
ith 75 dB prepulse and increasing intervals (30, 100, 300 and
00 ms)  between pre-pulse and pulse (ISI). The program automat-
cally recorded the startle response. Response to the 0 dB pulse
as the weight of the subject and was subtracted from subsequenttartle response data. Mean of the startle response to the 120 dB
ulse without prepulse was calculated for every subjects and con-
idered 100%, from which prepulse inhibition (PPI) was  calculated
y the following formula: PPI = 100 − ((startle after prepulse/startleResearch 300 (2016) 123–134 125
without prepulse) × 100). Mean PPI values were given for different
prepulse intensities.
2.4. Polymerase chain reaction (PCR)
After decapitation brains were quickly removed, whole FB (ros-
tral part of the brain from Bregma 0 mm)  and dorsal HC were
hand-dissected and ﬂash-frozen in dry ice, put in a sterile nuclease
free plastic tube and kept on −80 ◦C until processing. Frozen tis-
sue samples were homogenized in TRI Reagent Solution (Ambion,
USA) and total RNA was isolated with QIAGEN RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) according the manufacturer’s instruc-
tion. To eliminate genomic DNA contamination DNase I treatment
were used and 100 l RNase-free DNase I (1 unit DNase) (Thermo
Scientiﬁc, USA) solution was  added. Sample quality control and
the quantitative analysis were carried out by NanoDrop (Thermo
Scientiﬁc, USA). Ampliﬁcation was  not detected in the RT-minus
controls. The cDNA synthesis was performed with the High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems, USA).
Primers for the comparative Ct experiments were designed by
Primer Express 3.0 Program. Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) was  used as housekeeping gene.The DNMT1,
GAD1, catechol-O-methyltransferase (COMT), vesicular glutamate
transporter-1 (VGLUT1, SLC17A7 gene), serotonin receptor subtype
2A (5HT2A), brain-derived neurotrophic factor (BDNF) and GAPDH
primers (Microsynth, Switzerland) were used in the Real-Time PCR
reaction with Fast EvaGreen® qPCR Master Mix  (Biotium, USA),
while DNMT3a (Rn01027162 g1, Life Technologies) and GAPDH
(Rn01775763 g1, Life Technologies) by Light Cycler 480 Probes
Master (Roche) on ABI StepOnePlus instrument. The following
primer pairs were designed:
DNMT1 forward: AGCATTCCCGTACAGAGCAG
reverse: CGGGTTGAGCTTTGGGATTG
GAD1forward: TGAATCGAGCCCGTTCCTG
reverse: GGCTACGCCACACCAAGTAT
COMT forward: CGTGTTAAAACCCGTGTCTGC
reverse: AGCCAACGGCATCTCCTCAA
VGLUT1 forward: CCACGACCAATGTGCGAAAG
reverse: GAGTATCCGACCACCAGCAG
5HT2A forward: AGCTGATATGCTGCTGGGTTT
reverse: CACCGGTACCCATACAGGA
BDNF forward: AAACGTCCACGGACAAGGCA
reverse: TTCTGGTCCTCATCCAGCAGC
GAPDH forward: ACAGCCGCATCTTCTTGTGC
reverse: GCCTCACCCCATTTGATGTT
2.5. Western blot
Brain were handled as in case of PCR and the frozen tissues
were homogenized in 200 l of ice-cold extraction buffer con-
taining 250 mM sucrose, 50 mM Tris, pH 7.5, 25 mM KCl, 0.5 mM
PMSF, 0.9 mM NaB, as well as protease inhibitors (protease inhibitor
cocktail, Roche, Basel, Switzerland) and phosphatase inhibitors
(phosphatase inhibitor cocktail 1, Sigma). The nuclear fraction (pel-
let) was separated by centrifugation at 7700 × g for 1 min  (4 ◦C),
and re-suspended in 1 ml  0.4 N H2SO4 and incubated for 30 min
(4 ◦C). Samples were centrifuged at 14,000 × g for 30 min (4 ◦C).
250 l trichloroacetic acid (with 4 mg/ml  deoxycholate) was  added
to the supernatant, and incubated for 30 min (4 ◦C) to precipitate
protein. Samples were then spun at 14,000 × g for 30 min  (4 ◦C) to
pellet protein. Pellets were washed for 5 min  with 1 ml acidiﬁed
acetone (0.1% HCl), then for 5 min  with acetone. Between washes,
protein was collected by centrifuging 5 min  at 14,000 × g (4 ◦C),
and aspirating supernatant. After the last wash, the pellet was  re-
suspended in 200 l 10 mM Tris, pH 8.0, and incubated for 15 min  at
room temperature. Protein concentrations were determined using
1  Brain Research 300 (2016) 123–134
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Fig. 1. Daily locomotor activity (counts/minutes in each hour) was monitored in
vasopressin-deﬁcient (di/di) Brattleboro rats for 24 h by biotelemetric equipment.
Measurement was started in the 1st hour of dark period. No signiﬁcant differences
were observed between +/+ and di/di animals. Both genotypes follow the normal26 K. Demeter et al. / Behavioural
 Nanodrop. Equivalent amounts of protein (10 g) for each sam-
le were resolved with SDS-PAGE using 4–15% gradient Tris–HCl
els. After electrophoresis, proteins were transferred to nitrocel-
ulose membranes for 2 h at 50 V. Membranes were incubated in
locking buffer (LI-COR, Lincoln, Nebraska, USA) 1 h at room tem-
erature to block non-speciﬁc binding. The blots were reacted with
rimary antibodies (H3, ab1791, Abcam; AcH4K8, ab15823, Abcam,
cH4K12, 07-595, Millipore, 1:5000; H4, ab10158, Abcam, 1:10,000
nd AcH3, 06-599, Millipore, 1:20,000) overnight at 4 ◦C, then
mmunolabeled by chemiluminescence and followed by detection
ith ChemiDocTM XRS+ System with Image LabTM Software. The
cH3/H3 bands were detected at 17 kDa and the AcH4 band was
etected at 10 kDa. As there was no appropriate pan-AcH4 anti-
ody available, we measured two speciﬁc H4 acetylation site, the
ysine acetylation at 8 (AcH4K8) or 12 (AcH4K12) position. Ratios
f AcH3 or AcH4 to total H3 or H4 were calculated for each sample
nd analyzed across conditions.
.6. Immunohistochemistry (IHC)
Rats, who underwent PPI, were deeply anesthetized by a mix-
ure described by biotelemetry and trans-cardially perfused with
00 ml  saline followed by 300 ml  ice cold 4% (w/v) paraformalde-
yde (PFA; Molar Chemicals Ltd., Hungary) in phosphate buffered
aline (PBS). Aorta descendens was pinched by pean forceps. The
rains were removed from the skull, post-ﬁxed for 1 day in PFA
t 4 ◦C and cryoprotected in 30% glucose (w/v in PBS) containing
.1% (w/v) sodium-azide (Sigma–Aldrich, Inc., Hungary). Six series
f 30 m frozen sections were cut in the frontal plane on a slid-
ng microtome. Floating sections were incubated in PBS containing
.5% Triton X-100 and 0.5% H2O2 for 30 min. Non-speciﬁc antigens
ere blocked by 2% bovine serum albumin (BSA; Sigma–Aldrich) in
BS for 30 min  at room temperature. Sections were incubated for
2 h at 4 ◦C with anti-histone H3 (Acetyl-Lys9) antibody made in
abbit (1:5000, SAB4500347 Sigma–Aldrich, Inc., Hungary), diluted
n blocking solution. After thorough PBS washing sections were
ncubated for 1 h in biotinylated anti-rabbit IgG secondary anti-
ody (1:500) (Vector Laboratories). Next, sections were incubated
n avidin–biotin complex (1:1000) (ABC Vectastain Elite kit, Vec-
or Laboratories) diluted in 0.05 M Tris buffered saline (TBS, pH
.6) for 1 h at room temperature. H3K9ac immuno-positive cells
ere visualized by nickel enhanced 3,3′-diaminobenzidine (DAB).
ections were incubated for equal time in Tris-buffered solu-
ion containing 0.2 mg/ml  DAB, 0.1% nickel-ammonium-sulphate
nd 0.003% H2O2. Enzymatic reaction was stopped by thorough
BS washing. Sections were mounted on glass slides in chrome-
elatin solution [0.5% (w/v) gelatin (Sigma–Aldrich) and 1 mM
hromium(III) potassium sulfate dodecahydrate (Sigma–Aldrich)],
ehydrated by mixtures of xylol isomers and covered by DPX
ounting medium (Sigma–Aldrich, Inc., Hungary). Microscopic
mages were digitized by OLYMPUS CCD camera, and stained par-
icles were counted by means of the ScionImage software. The
ethods of quantiﬁcation of immune-positive cells see in Ref.
60].
.7. Statistical analysis
Data were analyzed by analysis of variance (ANOVA) using
he STATISTICA 12 software package (Tulsa, OK, USA). One (fac-
or genotype) or repeated measure (factor genotype and time
r new-old, or latency) ANOVA was conducted. For post-hoc
nalysis Newman–Keuls test was used. We  have analyzed the cor-
elation between immunohistochemical and PPI data by Pearson
orrelation. Data were expressed as mean±SEM and the level of
igniﬁcance was set at p < 0.05.circadian rhythm. Grey background denotes the dark period. ##p < 0.01 vs. light
period.
3. Results
3.1. Locomotor activity
The telemetric data did not show any signiﬁcant differences
between the genotypes at any studied timepoint of the day (Fig. 1).
The locomotor activity followed the normal lifecycles, thus, both
genotypes were signiﬁcantly more active during the dark phase
than in light (Ftime(23,115) = 10.00; p < 0.01). The genotype did not
inﬂuence this circadian variation (no genotype × time interaction).
3.2. Novel object recognition test
In the sampling phase of NOR +/+ and di/di animals spent
same time with the Object 1 (old) (Fig. 2A). During the test phase
(Fig. 2B) repeated measure ANOVA showed a signiﬁcant differ-
ence between the time spent snifﬁng the new and the old object
(Fnew-old(1,14) = 4.73; p < 0.05) with a tendency of its interaction with
the genotype (Fnew-old×genotype(1,14) = 4.24; p = 0.059). Post-hoc anal-
ysis showed that during the test phase di/di animals spent same
time with old and new object, while +/+ rats sniffed more the new
one (p < 0.01). Furthermore, +/+ and di/di animals spent almost sim-
ilar time with the new object, but di/di rats explored signiﬁcantly
more time the old one than the +/+ (p < 0.05). The calculated dis-
crimination index showed that di/di rats had signiﬁcantly weaker
ability to distinguish new from old object (Fgenotype(1,14) = 11.52;
p < 0.01) (Fig. 2C).
3.3. Social recognition test
Similarly to NOR, in the sampling phase of SR +/+ and di/di
animals interacted the same time with the Animal 1 (old)
(Fig. 2D). Repeated measure ANOVA showed a signiﬁcant differ-
ence between the time spent snifﬁng the new and the old juvenile
(Fnew-old(1,11) = 21.61; p < 0.01), which was detectable only in +/+
animals (Fnew-old × genotype(1,11) = 8.01; p < 0.05). Post-hoc analysis
showed that during the test phase di/di animals spent the same
time with old than with new juvenile, while +/+ rats interact more
with the new one (p < 0.01) (Fig. 2E). Discrimination index revealed
that di/di rats had signiﬁcantly weaker ability to distinguish old
animal from the new (Fgenotype(1,11) = 14.17; p < 0.01)(Fig. 2F).
K. Demeter et al. / Behavioural Brain Research 300 (2016) 123–134 127
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Fig. 2. Novel object (A–C) and social recognition tests (D–F). (A) During the sampling phase vasopressin-deﬁcient (di/di) and control (+/+) Brattleboro rats observed same
time  (in time% of whole test) the unknown object. (B) In the test phase di/di rats spent signiﬁcantly less time with the new object, they did not distinguish novel object from
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(he  familiar one. Moreover, di/di animals spent signiﬁcantly more time with old obj
ew  from old object. (D) In sampling phase +/+ and di/di animals spent same time
ime  with new juvenile, while di/di rats could not distinguish new and old animals
as  close to 0. ##p < 0.01 time% snifﬁng new vs. old object (B) or old juvenile (E); *
.4. Social avoidance test
The AVP-deﬁcient di/di rats enter less frequently
Fgenotype(1,13) = 5.55; p < 0.05) (Fig. 3A), spent less time
Fgenotype(1,13) = 5.10; p < 0.05) in the large compartment
Fig. 3B) and sniffed signiﬁcantly less the unfamiliar male
Fgenotype(1,13) = 4.69; p < 0.05) than their +/+ counterpairs.n +/+. (C) Discrimination index conﬁrmed that di/di ratswere unable to distinguish
snifﬁng of conspeciﬁc. (E) During test phase +/+ rats interacted signiﬁcantly more
 behavior was conﬁrmed by discrimination index (F), where the value of di/di rats
5, **p < 0.01 genotype difference.
3.5. Prepulse inhibition test
Prepulse inhibition was less effective in di/di rats compared with
+/+ animals, especially at lower prepulse intensity level (73 dB:
Fgenotype(1,18) = 7.10; p < 0.05, 77 dB: Fgenotype(1,18) = 2.44; p = 0.14,
81 dB: Fgenotype(1,18) = 4.18; p = 0.06) (Fig. 3C). We investigated the
effect of increasing inter-stimulus interval (ISI) at 75 dB prepulse
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Fig. 3. Social avoidance (A, B) and prepulse inhibition (C, D) tests in vasopressin-deﬁcient (di/di) Brattleboro rats. (A) The di/di rats entered signiﬁcantly less time into the
large  cage, containing the separated unfamiliar male. (B) The di/di rats spent and interacted less time (in time% of whole test) with the unfamiliar conspeciﬁc than di/di rats.
( easin
i enoty
a
i
i
a
r
t
a
3
M
l
3
5
t
s
w
a
3
l
o
d
a
eC)  Increased prepulse intensity reduced the difference between genotypes. (D) Incr
nhibition in +/+ rats, while did not change the PPI in di/di rats. *p < 0.05, **p < 0.01 g
nd 120 dB pulse on PPI (Fig. 3D). The response of +/+ rats at
ncreasing latency inversely correlated with PPI. There were signif-
cant differences between genotypes (Fgenotype(1,17) = 9.76; p < 0.01)
s the PPI of di/di rats did not react to changes in ITI. It was
eﬂected also by a signiﬁcant interaction between ISI and geno-
ype (FISI×genotype(3,51) = 4.25; p < 0.01). Post-hoc analysis showed
 signiﬁcant decrease of PPI in +/+ rats, when we compared the
0 ms  ISI with 300 ms  and 500 ms  latency (p < 0.01 both cases).
oreover, the genotype difference disappeared at 300 and 500 ms
atencies.
.6. qRT-PCR
Fold changes of expression of dnmt1,  dnmt3a, gad1, comt, vglut1,
ht2a and bdnf genes were investigated in FB and in HC, correlated
o +/+ animals (Fig. 4A and B). DNMT1 in the frontal area showed
igniﬁcantly lower level in di/di rats (Fgenotype(1,10) = 8.71; p < 0.05),
hile in the HC and the other 6 gene transcript in both investigated
rea, showed no signiﬁcant differences.
.7. Western blot
In the FB of di/di rats the pan-AcH3/H4 ratio was signiﬁcantly
ower than in +/+ ones (Fgenotype(1,7) = 7.32; p < 0.05) (Fig. 4C). On the
ther hand, in the HC this pan-AcH3/H4 ratio was much higher in
i/di rats than in +/+ ones (Fgenotype(1,12) = 23.87; p < 0.01). AcH4K12
nd AcH4K8 ratio compared to H3 did not show signiﬁcant differ-
nces neither in the FB nor in the HC.g interstimulus interval (ISI latency) followed by 75 dB prepulse tone decreases the
pe difference. ##p < 0.01 vs. 30 ms  ISI latency.
3.8. Immunohistochemistry
The following brain regions were investigated (Fig. 5E): nucleus
accumbens core (AcbC) and shell (AcbS) regions, prelimbic cor-
tex (PrL), infralimbic cortex (IL) and dorsal peduncular cortex
(DP), dorsal (LSD), intermediate (LSI) and ventral (LSV) part of the
lateral septum, as well as CA1, CA2 and CA3 ﬁelds of the dor-
salHC.
In the di/di animals AcH3K9 immunostaining showed signiﬁ-
cantly less labeled cells in the dorsal peduncular cortex (DP) of the
PFC than in the +/+ rats (Fgenotype(1,16) = 5.24; p < 0.05) (Fig. 5A). In
the other investigated PFC areas (PrLand IL) no differences were
detected between the genotypes. AcH3K9 immunohistochemistry
did not show signiﬁcant differences between di/di and +/+ animals
neither in the whole Acb nor in the separately investigated core
and shell (Fig. 5B). In the lateral septum only in LSV compartment
were signiﬁcantly less AcH3K9 immunopositive cells in di/di than
in +/+ rats (Fgenotype(1,16) = 5.37; p < 0.05) (Fig. 5C). In the CA1 there
was signiﬁcantly more AcH3K9 labeled cell in di/di rats than +/+
(Fgenotype(1,15) = 5.81; p < 0.05), while in CA2 and CA3 there was no
genotype effect (Fig. 5D).
There was a negative correlation between the ISI parameter of
PPI test and the number of AcH3K9 immunopositive cells in the CA1
(vs. 75 dB 100 ms  ISI r = −0.63, p < 0.01, vs. 75 dB 300 ms  ISI r = −0.50,
p < 0.05). Marginal negative correlation was  measured between PFC
and the 75 dB 300 ms  ISI (r = −0.44, p = 0.078).
We  had correlated the values of the investigated brain areas
(see Table 1). There was a signiﬁcant positive correlation between
DP area and AcbC (r = 0.47, p < 0.05), LSI (r = 0.48, p < 0.05) and LSV
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Fig. 4. mRNA level identiﬁed by qRT-PCR in the frontal (A) and hippocampal (B) part of the brain of vasopressin-deﬁcient (di/di) Brattleboro rats and protein ratio of acetylated
histones measured by western blot (C). (A) At frontal part DMNT1 level decreased signiﬁcantly in di/di animals, while DNMT3a, GAD1, COMT, VGLUT1, 5HT2A and BDNF
m as obs
(  H4 (a
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aRNA  level were identical in the two genotypes. (B) In the HC no genotype effect w
FB)  and increased in the hippocampus (HC) of di/di rats. Histone modiﬁcation on
igniﬁcant differences. *p < 0.05, **p < 0.01 genotype difference.r = 0.55, p < 0.05). The core region of the accumbens signiﬁcantly
orrelated with CA3 (r = 0.61, p < 0.05), while the shell region pos-
tively correlated with LSD (r = 0.50, p < 0.05), LSI (r = 0.70, p < 0.01)
nd LSV (r = 0.50, p < 0.05).erved. (C) H3 compared to total H4 signiﬁcantly decreased in the frontal brain area
cetylation on lysine 8 or 12) compared with whole H3 protein level did not show4. Discussion
Combining behavioral studies with molecular biological tech-
niques we  demonstrated that in Brattleboro rat the lifelong
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Fig. 5. Acetylated lysine 9 of histone 3 (AcH3K9) immunohistochemistry in vasopressin-deﬁcient (di/di) Brattleboro rat brain. (A) Among the prefrontal cortex (PFC) regions
in  the dorsal peduncular part (DP) di/di rats revealed lower levels, while prelimbic (PrL) and infralimbic (IL) region showed equal number of AcH3K9 immunopositive cell
number in both genotypes. (B) Nucleus accumbens (Acb) shell (AcbS) and core (AcbC) did not show signiﬁcant difference between the genotypes. (C) In the lateral septum only
the  ventral (LSV) but not the dorsal (LSD) or intermediate (LSI) parts showed alterations. (D) In the CA1 region of the HC the AcH3K9 level was increased. (E) 3D reconstruction
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snd  position of the investigated nuclei in the rat brain. For better overview only u
ncrease, while blue the signiﬁcant decrease of the number of AcH3K9 immunopos
he  references to color in this ﬁgure legend, the reader is referred to the web  versio
rameshift mutation in the gene coding for the neuropeptide AVP
esulted in epigenetic alteration in the frontal part of the brain
DP, LSV) and in the hippocampus (CA1), which can underline the
ppearance of SCZ-like behavior in Brattleboro rats.
Earlier observations (for references see introduction) and our
ecent study conﬁrmed lots of similarities between SCZ patients
nd the SCZ-like behavior of di/di rats. However, previous work
oncentrated on a single test (mostly on PPI), but SCZ is a spectrum
isorder, thus, we have to take into consideration a wide range of
ehaviors [61]. In this sense, our work is the ﬁrst summary pre-
enting in a single colony a wide range of SCZ-like behavior in theral nuclei was shown, from caudo-lateral view. Red color indicates the signiﬁcant
cells in the appropriate nuclei. *p < 0.05 genotype difference. (For interpretation of
is article.)
Brattleboro rat from all domains (positive, negative and cognitive).
Cognitive impairment has drawn attention as particularly impor-
tant being one of the more treatment resistant components. In the
present study cognitive symptoms were studied by NOR and SR,
showing that our colony has SCZ-like deﬁciencies similarly to pre-
vious observations [42,58,62–64]. Another negative symptom, the
lack of interest to conspeciﬁc was  conﬁrmed by SA test, which was
never used in this strain before, although social impairment was
already described in Brattleboro rat [58,65,66]. In our colony the
attention deﬁcit was also conﬁrmed by PPI test as the main behav-
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Table  1
Matrix of the correlation among the AcH3K9 immunohistochemically stained brain areas.
FB PFC PrL IL DP Acb AcbC AcbS LS LSD LSI LSV HC CA1 CA2 CA3
FB
PFC
PrL
IL +
DP + +
Acb
AcbC +
AcbS +
LS + +
LSD +
LSI + + + +
LSV + + + +
HC
CA1
CA2
CA3 + + +
Light grey cells indicate the non-signiﬁcant, while dark gray cells the signiﬁcant correlations. “+” indicates that the correlation is positive. Black ﬁlled cells sign the meaningless
comparison. FB means frontal part of the brain (PFC + Acb + LS). PFC means the summarized data of PrL + IL + DP. Acb is the summary of AcbC and AcbS, LS is LSD + LSI + LSV,
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thile  HC is the summary of CA1 + CA2 + CA3.
bbreviations: Acb—nucleus accumbens, AcbC—Acb core, AcbS—Acb shell; PFC—pref
S—lateral septum, LSD—LS dorsal part, LSI—LS intermediate part, LSV—LS ventral p
oral model of SCZ used not only in preclinical, but also in clinical
esearch [67,68].
The negative correlation between PPI and PFC AcH3K9
mmunoreactivity in our colony was in good agreement with the
ole of epigenome, especially histone acetylation, in cognitive pro-
esses [69,70]. Although in humans the methylation “maintaining”
nzyme, DNMT1 [14,71], as well as the de novo methyltransferase
NMT3 [72] were increased in the PFC of SCZ patients, in Brattle-
oro rats an opposite change, namely a decrease was detectable
n DNMT1 of the frontal region. Therefore we were focusing on
cetylation, while methylation processes seemed to have subtle
ontribution to the development of SCZ-like symptoms in Brat-
leboro rats. Moreover, based upon our Western blot analysis, H3
ather than H4 acetylation seemed to be important. An elevated
DAC1 level in the PFC, observed in postmortem brain samples
f SCZ patient [73], might contribute to reduced H3 acetylation
n the FB of di/di animals, however, it was not examined in our
tudy.We have chosen to study the acetylation of a single lysine
esidue (AcH3K9), because Aoyoma et al. [19] using a pharmaco-
ogical model of SCZ (piperidine hydrochloride (PCP) in mouse)
ound decreased level of AcH3K9 in the PFC. Moreover, previous
bservation found a decrease of AcH3K9 in human SCZ patients
74]. Our results in di/di rats were in good agreement both with the
harmacological model and human data.
However, despite the GABAergic origin hypothesis [75] we were
nable to ﬁnd alteration in the GABA synthetizing enzyme, GAD1
RNA level. Although deﬁcit in GABAergic system is one of the
ost commonly described abnormality in SCZ patients [76], and
AD1 thought to be down regulated because of the increased level
f DNMT1 [71], but in Brattleboro rats an enhanced rather than
educed GABA level was reported [77] in good agreement with the
ound lower DNMT1 levels. Therefore we might assume that the
etected lower acetylation in the FB could decrease other gene
xpression leading to reduced adaptive capacity to the suddenly
hanging environment. As summarized in [14] alteration of DNA
ethylation may  be involved in epigenetic alterations of the glu-
amate and serotonin neurotransmitter system as well. We  havel cortex, PrL—prelimbic cortex, IL—infralimbic cortex, DP—dorsal peduncular cortex;
C—hippocampus, CA1-3—cornu ammonis of hippocampus.
investigated the mRNA level of key component of these systems
the VGLUT1 and 5HT2A receptor, respectively, but no signiﬁcant
changes were observed. Furthermore, we examined mRNA level
of BDNF gene that known to play an important role in cognition.
Previous studies showed the hypermethylation of its genes in the
etiology and pathogenesis of SCZ [9], but we did not ﬁnd signiﬁcant
alteration in di/di animals, either.
Both in human patients and animal models of SCZ dysfunction
of the dopaminergic system was observed [78] and the currently
used antipsychotics antagonize dopamine receptors [79]. In the
PCP model of SCZ the low AcH3K9 caused dysfunction of the
dopaminergic systems and the atypical antipsychotic clozapine
ameliorated the AcH3K9 level mainly on D1 receptor positive
cells in the PFC [19]. It is also known, that D1  signaling regulates
histone modiﬁcation [80] and we also have found signiﬁcant pos-
itive correlation (see Table 1) in the number of AcH3K9 positive
cells between elements of the dopaminergic system (DP, Acb, LS).
Although we  did not measured signiﬁcant alteration in the mRNA
level of dopamine degrading enzyme COMT neither in the FB nor
in the HC, we can hypothesize that in Brattleboro rats the lack of
AVP induces epigenetic modiﬁcation leading to disturbances of the
dopaminergic system, which contributes to the SCZ-like behavioral
alterations. Indeed, higher dopamine content [81,82] and upregu-
lated dopamine receptors [45] were reported in di/di animals.
In the following we have examined in details those brain areas,
which are thought to be involved in the development of SCZ. We
have found signiﬁcant decrease in the number of AcH3K9 posi-
tive cells in the DP of di/di rats. The role of the DP is less known
and investigated than the neighboring IL and PrL despite their
structural similarities [83]. Ventral part of the PFC speciﬁcally
responsible for a ﬂexible shifting to new strategies related to spatial
cues, furthermore—on the basis of its connections with autonomic
centers—for the integration of internal physiological states with
salient environmental cues for the guidance of behavior [84]. DP
shares projections relevant to reward circuitry such as glutamater-
gic afferents to the ventral tegmental area [85]. Furthermore, the IL
and DP both project heavily to the AcbS [86].
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There is lots of evidence that the Acb (because its dopamine con-
ent) is involved in the pathology of SCZ [87,88]. Although alteration
f dopamine receptors in the Acb was found in di/di rats [45], but
e did not ﬁnd signiﬁcant genotype difference in the number of
cH3K9 labeled cells. It seems that in Brattleboro rat, AcH3K9 alter-
tion is not involved in the development of symptoms, but changes
t other lysine residues might have some importance.
LSV plays an important role in various behavioral processes [89],
ntegrates sensory stimuli conveying this information to respon-
ible brain areas to direct motivating behaviors. LSV, showing
igniﬁcantly lower AcH3K9 reactivity in di/di than control rats,
as activated (measured by c-Fos immunochemistry) during PPI
90]. Medial PFC sends glutamatergic projections to LS [89], thus,
he lower cell activity of DP induced by decreased acetylation
ight lead to reduced acetylation/activation of LSV neurons. LS is
trongly interconnected with the HC predominantly by inhibitory
ABAergic neurons [91], which connection has an established role
n learning and memory [92]. Moreover, the septo-hippocampal
CA1) GABAergic neurons were activated during locomotion and
alient sensory event in behaving mice [93].
Thus, it is not surprising, that reduced inhibitory GABAergic tone
n the HC lead to enhanced pan-AcH3 and especially AcH3K9 level
n the CA1 of di/di rats compared to control animals. According to
he literature during HC dependent memory formation (e.g., con-
extual fear conditioning or NOR) AcH3 level increased in the CA1,
hile AcH4 was unaltered [69]. This suggests that H3 acetylation
ccurs during chronic events [9], like the chronic stress of diabetes
nsipidus in di/di rats. These data, along with postmortem analy-
es [55,73], suggested that histone modiﬁcations in the HC might
lso contribute to the behavioral alteration in SCZ through aberrant
egulation of one or more genes. Indeed, epigenetic mechanisms
ere initially described for their ability to promote differentia-
ion including neurogenesis and HC is one of the two regions in
hich generation of new functional neurons from neural stem cells
ccurs throughout the adult life. Adult hippocampal neurogenesis
ontributes to learning and memory, core features of SCZ [94,95].
Positive symptoms such as auditory hallucinations have been
orrelated with abnormal activation patterns in PFC [96], fur-
hermore delusional states and negative symptoms (e.g., avolition
nd apathy) also appear to be involved in prefrontal dysfunc-
ion [97]. The volume of the gray matter [98] and the cerebral
lood ﬂow [99] is reduced in the PFC of SCZ patients, known as
ypofrontality. Our SCZ model, the di/di Brattleboro rat has also
maller brain volume, compared to +/+ animals [100]. Although
yperlocomotion is thought to reﬂect positive symptom, but,
espite some previous observations (in adults [101] and in pups
102,103]), we were unable to detect changes in locomotion not
nly in different test situations [104,105], but also during a long-
erm observation by biotelemetry for 24 h. Nevertheless, when
e used a hyperlocomotion-inducing NMDA antagonist (ketamine
p 10 mg/kg/2 ml  saline right before the 15 min  openﬁeld test; a
odel of positive symptoms [106]) the di/di rats did not show an
nhancement of locomotion (number of line crossing in control:
30.7 ± 74.6; in di/di: 335.7 ± 63.2), which can be supposed in an
lready SCZ-like subject [61].
. Conclusion
We  can propose that the AVP deﬁcient Brattleboro rat strain is
 valuable model (i) to study the development of SCZ-like behav-
or, to establish new test battery for SCZ, (ii) follow the changes in
pigenetic state of affected genes, and (iii) test newly discovered
ntipsychotics. This is hotspot as inﬂuencing HDACs may  provide
herapeutic alternatives for treating many of the symptoms asso-
iated with SCZ, particularly cognitive deﬁcits [107]. Our studiesResearch 300 (2016) 123–134
conﬁrmed that no single gene, more probably ﬁne changes in an
array of molecules are responsible for the majority of SCZ cases.
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